A double-blind randomized study comparing plasma level-targeted dose imipramine and high-dose venlafaxine in depressed inpatients

Journal of Psychiatric Research

Volumn 47, Issue 10, 2013, Pages 1337-1342

  Vermeiden, Marlijn ^a   Mulder, Paul G ^a   van den Broek, Walter W ^a   Bruijn, Jan A ^a   Birkenhäger, Tom K ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Imipramine; Inpatients; Major depression; Plasma level targeted trial; Venlafaxine

Indexed keywords

BENZODIAZEPINE; DESIPRAMINE; HALOPERIDOL; IMIPRAMINE; LORAZEPAM; VENLAFAXINE;

ADULT; AGED; AGITATION; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; URINE RETENTION; XEROSTOMIA;

IMIPRAMINE; INPATIENTS; MAJOR DEPRESSION; PLASMA LEVEL TARGETED TRIAL; VENLAFAXINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIPRAMINE; INPATIENTS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 84881554237     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.05.029     Document Type: Article

References (24)

1. Anderson I.M. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression and Anxiety 1998, 7(Suppl. 1):11-17.
2. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 2000, 58:19-36.
3. Angst J. Severity of depression and benzodiazepine co-medication in relationship to efficacy of antidepressants in acute trials. Human Psychopharmacology 1993, 8:401-407.
4. Benkert O., Grunder G., Wetzel H., Hackett D. Arandomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research 1996, 30:441-451.
5. Birkenhäger T.K., Van Den Broek W.W., Moleman P., Vulto A.G., Bruijn J.A. Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?. Psychopharmacology 2005, 181:595-599.
6. Bruijn J.A., Moleman P., Mulder P.G., Van Den Broek W.W., Van Hulst A.M., Van Der Mast R.C., et al. Adouble-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology 1996, 127:231-237.
7. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders 1999, Dutch translation, Swets & Zeitlinger.
8. Gex-Fabry M., Balant-Gorgia A.E., Balant L.P., Rudaz S., Veuthey J.L., Bertschy G. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. European Journal of Clinical Pharmacology 2004, 59:883-891.
9. Harrison C.L., Ferrier N., Young A.H. Tolerability of high-dose venlafaxine in depressed patients. Journal of Psychopharmacology 2004, 18:200-204.
10. Harvey A.T., Rudolph R.L., Preskorn S.H. Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry 2000, 57:503-509.
11. Hiemke C., Baumann P., Bergemann N., Conca A., Dietmaier O., Egberts K., et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011, 44:195-235.
12. Lecrubier Y., Bourin M., Moon C.A., Schifano F., Blanchard C., Danjou P., et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatrica Scandinavica 1997, 95:485-493.
13. Niklson J.A., Reimitz P.E., Semnef C. Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Psychopharmacology Bulletin 1997, 33:41-51.
14. Perry P.J., Zeilmann C., Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. Journal of Clinical Psychopharmacology 1994, 14:230-240.
15. Potter W.Z., Rudorfer M.V., Manji H. The pharmacologic treatment of depression. The New England Journal of Medicine 1991, 325:633-642.
16. Preskorn S.H., Burke M.J., Fast G.A. Therapeutic drug monitoring. Principles and practice. Psychiatric Clinics of North America 1993, 16:611-645.
17. Preskorn S.H., Irwin G.H., Simpson S., Friesen D., Rinne J., Jerkovich G. Medical therapies for mood disorders alter the blood-brain barrier. Science 1981, 213:469-471.
18. Rudolph R.L., Fabre L.F., Feighner J.P., Rickels K., Entsuah R., Derivan A.T. Arandomized placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of Clinical Psychiatry 1998, 59:116-122.
19. Stahl S.M., Entsuah R., Rudolph R.L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biological Psychiatry 2002, 52:1166-1174.
20. Schweizer E., Feighner J., Mandos L.A., Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of Clinical Psychiatry 1994, 55:104-108.
21. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001, 178:234-241.
22. Van Den Broek W.W., Birkenhäger T.K., Mulder P.G., Bruijn J.A., Moleman P. Adouble-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology 2004, 175:481-486.
23. van den Broek W.W., Mulder P.G., van Os E., Birkenhäger T.K., Pluijms E.M., Bruijn J.A. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis. Journal of Psychopharmacology 2009, 23:708-713.
24. Wijkstra J., Burger H., van den Broek W.W., Birkenhäger T.K., Janzing J.G., Boks M.P., et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica 2010, 121:190-200.